VNDA Stock Analysis: Buy, Sell, or Hold?
VNDA - Vanda Pharmaceuticals Inc.
$5.28
-0.10 (-1.86%)
âŧ
5d:
+1.15%
30d:
-1.49%
90d:
-14.98%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 05, 2026
0d
Get Alerted When VNDA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: VNDA is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: VNDA is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: VNDA is currently trading at $5.28, which is considered fair relative to its 30-day fair value range of $5.06 to $5.50.
Technical Outlook: Technically, VNDA is in a strong downtrend. Immediate support is located at $4.80, while resistance sits at $5.59.
Market Sentiment: VNDA scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $12.19 (+130.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, VNDA is in a strong downtrend. Immediate support is located at $4.80, while resistance sits at $5.59.
Market Sentiment: VNDA scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $12.19 (+130.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$5.06 -
$5.50
Company Quality Score
36/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
60.4%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 130.8% below Wall St target ($12.19)
- WARNING: Composite score 36/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$5.06 -
$5.50
Current vs Trading Range
FAIR
Expected Move (7 Days)
Âą$0.53
(10.1%)
Support & Resistance Levels
Support Level
$4.80
Resistance Level
$5.59
Current Trend
Strong Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.13
Wall Street Target
$12.19
(+130.8%)
Revenue Growth (YoY)
-3.9%
Earnings Growth (YoY)
-95.9%
Profit Margin
-127.4%
Share & Embed Analysis
Last updated: August 22, 2026 10:26 PM ET
Data refreshes hourly during market hours. Next update: 11:26 PM
Data refreshes hourly during market hours. Next update: 11:26 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is VNDA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
5
Sells
Net
INSIDERS SELLING
Recent Transactions
Gunther Birznieks
SELL
42431 shares
2026-03-02
Joakim Wijkstrom
SELL
30800 shares
2026-03-02
Kevin Patrick Moran
SELL
42442 shares
2026-03-02
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 58 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$53 | 57 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
RCKT
Rocket Pharmaceuticals IâĻ |
STRONG BUY
18 analysts |
$9 | 53 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$89 | 40 SELL |
